Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway

Fig. 4

The effects of Celastrol on liver function and liver index in the DN rat model. a liver index, b ALT, and c AST. NC group, normal control rats; DN group, high-fat and high-glucose diet-fed STZ-induced DN rats. DN + CL group, DN rats were given by gavage low dose (0.5 mg/kg/d) Celastrol; DN + CH group, DN rats were given by gavage high dose (1.5 mg/kg/d) Celastrol. DN + INH group, DN rats were intraperitoneally injected with LY294002 (1.2 mg/kg/d). Following the once per day administration of Celastrol or LY294002 for 4 weeks for the intervention, rats were sacrificed and the liver index assayed. Prior to sacrificing, ALT and AST were determined. Values are presented as mean ± SEM. * p < 0.05, ** p < 0.01 compared to NC group, # p < 0.05, ## p < 0.01 compared to DN group. DN, diabetic nephropathy. We used the one-way analysis of variance (ANOVA), followed by Turkey’s multiple comparison test to analyze the differences

Back to article page